A phase III clinical study to compare the combination therapy of eribulin mesylate + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumab
Phase of Trial: Phase III
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms EMERALD
- 27 Nov 2018 According to an Eisai media release, new study results will be presented during the 41st San Antonio Breast Cancer Symposium (SABCS).
- 31 Aug 2018 Biomarkers information updated
- 02 Aug 2017 Status changed from not yet recruiting to recruiting.